Name: Combating Resistant Pathogens: Exploring the Efficacy of Eravacycline Utilization in Multidrug-Resistant Infections
Start: 2025-04-24T09:10:00-0400
End: 2025-04-24T09:25:00-0400

You will be able to validate your attendance (Check-In to sessions) using your personal schedule.

Thursday April 24, 2025 9:10am - 9:25am EDT

Athena A

Title: Combating Resistant Pathogens: Exploring the Efficacy of Eravacycline Utilization in Multidrug-Resistant Infections
Authors’ names: Kiara Patino, Ryan Vathy, Ben Albrecht, Sujit Suchindran, Sarah B. Green
Background/Purpose: Eravacycline, FDA-approved for complicated intra-abdominal infections, is increasingly used off-label for multidrug-resistant (MDR) infections, including carbapenem-resistant Enterobacterales (CRE), Stenotrophomonas maltophilia and carbapenem-resistant Acinetobacter baumannii (CRAB). Eravacycline has been utilized at Emory Healthcare (EHC) hospitals, an academically affiliated healthcare system based in Atlanta, GA, for these MDR infections with limited treatment options. The objective of this study is to evaluate the efficacy and safety of eravacycline utilization for off label treatment of infections caused by MDR organisms at EHC hospitals.
Methods: This study is an institutional review board approved, multi-center, retrospective quasi-experimental analysis. Adult patients (≥ 18 years of age) who received eravacycline at an EHC hospital from October 1st, 2022, to June 30th, 2024, for the treatment of infections due to vancomycin-resistant Enterococcus (VRE), CRAB, CRE, MDR Enterobacterales, or S. maltophilia were included in this study. Patients who received < 72 hours of treatment with eravacycline were excluded. The primary endpoint was a composite of treatment failure defined as inpatient mortality during the index admission and/or 30-day microbiologic recurrence. Secondary outcomes included safety endpoints such as antibiotic associated adverse effects, infusion site reactions, and Clostridioides difficile infection diagnosis within 90 days. Descriptive statistics were used to evaluate the primary and secondary outcomes, and a multivariate regression analysis was used to assess risk factors for treatment failure with eravacycline.
Results: 48 patients were included in this study. The patients’ median age was 57.6 years, with 60.4% female and 54.2% Black. Eravacycline was primarily used for VRE (31.3%), S. maltophilia (29.2%), and CRE (20.8%) infections. The median treatment duration with eravacycline was 12.6 days. Treatment failure occurred in 39.6% of patients, while 60.4% of patient experienced survival without recurrence. Adverse events were rare (4.2%). No significant factors for treatment failure were identified in multivariate analysis.
Conclusions: Eravacycline is a well-tolerated option for treating MDR infections. Given its favorable safety profile, eravacycline is a promising alternative for infections with limited treatment options.
Contact email: kiara.patino@emoryhealthcare.org

Moderators